Minkyu Park

Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Verona Pharma’s $150 million follow-on offering of 14,260,000 American depositary shares at a public offering price of $10.50 per American depositary share. Verona is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Lawyers Daniel Goldberg, Eric Blanchard, Div Gupta, Charlie Kim, Minkyu Park, Amiti Rothstein and Olivia Creser led the Cooley team.